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Patients' characteristics according to pre-transplantation iPTH levels

                                                    Intact parathyroid hormone pre-transplant                               
  ------------------------------------------------- ------------------------------------------- --------------------------- --------
  Age (years)                                       49.8 ± 14.3                                 45.0 ± 15.5                 0.08
  Male gender, *N* (%)                              54 (57)                                     20 (36)                     0.02
   African American, *N* (%)                        45 (48)                                     20 (36)                     
   Caucasian, *N* (%)                               38 (40)                                     31 (56)                     0.19
   Other, *N* (%)                                   11 (12)                                     4 (8)                       
  Diabetes mellitus, *N* (%)                        22 (24)                                     13 (26)                     0.81
  Hypertension, *N* (%)                             66 (71)                                     42 (82)                     0.13
  Donor type, *N* (%)                                                                                                       
   Cadaveric donor                                  70 (74)                                     36 (65)                     0.29
   Living donor                                     25 (26)                                     19 (34)                     
  Time from transplant (months)                     41.7 ± 40.5                                 49.5 ± 30.8                 0.27
  Time on dialysis (years)                          4.6 ± 11.7                                  2.8 ± 2.9                   0.41
  Haemodialysis                                     74%                                         47%                         0.001
  Peritoneal dialysis                               21%                                         29%                         0.49
  Pre-emptive transplant                            5%                                          24%                         0.002
  Serum creatinine (mg/dL)                          1.93 ± 1.68                                 1.51 ± 1.17                 0.14
  eGFR (mL/min/1.73 m^2^)                           52.8 ± 22.4                                 56.6 ± 20.8                 0.36
  Most recent corrected serum calcium (mmol/L)      2.3 ± 0.3                                   2.3 ± 0.2                   0.24
  Pre-transplant corrected serum calcium (mmol/L)   2.3 ± 0.4                                   2.2 ± 0.3                   0.68
  Most recent serum phosphorus (mmol/L)             1.06 ± 0.42                                 1.16 ± 0.29                 0.14
  Pre-transplant serum phosphorus (mmol/L)          1.74 ± 0.58                                 1.77 ± 0.61                 0.90
  Serum albumin (g/dL)                              3.6 ± 0.5                                   3.5 ± 0.6                   0.33
  Pre-transplant iPTH pg/mL                         191 ± 203 (range 65--1613)                  42 ± 11 (range 3--62)       0.0001
  Follow-up iPTH pg/mL                              239 ± 249 (range 28--1493)                  107 ± 134 (range 13--739)   0.0001
  Change in iPTH category                           17 (18%)                                    12 (24%)                    0.0001

Numbers are expressed as absolute values, percentages, mean ± SD and range where indicated.

Sir,

Secondary hyperparathyroidism (SHPT) and its associated bone and vascular complications are highly prevalent in patients undergoing renal replacement therapy. Whether successful kidney transplantation corrects SHPT in the majority of patients with a functioning graft is unclear. In the context of an ongoing, randomized study on the effects of vitamin D therapy in post-transplant patients, we reviewed the clinical data of 150 consecutive kidney or kidney--pancreas transplant recipients with a functioning graft a minimum of 1 year after transplantation at our institution. Table [1](#T1){ref-type="table"} presents patients' characteristics displayed according to a pre-transplantation iPTH level \< or ≥65 pg/ mL (upper limit of normal). As shown, despite a similar and acceptable post-transplant eGFR and optimal serum levels of calcium and phosphate, only 17% of the patients in the higher iPTH category regressed to normal, while 24% of the patients with low iPTH before transplantation moved to the higher category over time. In a multivariable model that included nine variables \[age, gender, diabetes mellitus, iPTH\< or ≥65 pg/mL at time of transplantation, most recent serum calcium (albumin corrected), most recent serum phosphorus, most recent creatinine, most recent eGFR and haemodialysis\], we identified male gender \[beta coefficient 2.67 (1.12--6.38); *P* \< 0.03\], pre-transplant haemodialysis \[beta coefficient 2.25 (0.95--5.30); *P* = 0.06\] and iPTH ≥65 pg/mL prior to transplantation \[beta coefficient 11.48 (4.79--27.53); *P* \< 0.001\] as independent variables predicting iPTH ≥65 pg/mL at follow-up (model *X*^2^ = 46.56; *P* \< 0.001). The limited available literature suggests that the risk of persistent SHPT post-transplantation is associated with high serum levels of calcium and phosphorus prior to transplantation and sub-optimal graft function post-transplantation \[[@R1]\]. However, when we repeated our multivariable analyses including pre-transplantation serum calcium and phosphorus, the results did not change. Some investigators suggested that 25% \[[@R2]\] to 50% \[[@R3]\] of transplant recipients demonstrate elevated iPTH long term, although our data would suggest a much higher incidence. Potential explanations include adenomatous transformation of parathyroid nodules that may be only partially reversible, reduced intestinal absorption of calcium induced by steroid therapy and persistent relative vitamin D deficiency. Despite the known dissociation between iPTH levels and bone histology, early intervention to reduce the incidence of SHPT in post-transplantation with vitamin D receptor activators or calcimimetics may be very important to reduce the incidence of osteoporotic fractures and vasculopathy in these patients \[[@R4]\].
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